2 January 2014
Smiths Medical has gained a key US Food and Drug Administration (FDA) approval for a customisable infusion system that helps maintain effective epidural analgesia during labour and delivery or with post-operative pain management.
The FDA 510(k) clearance allows Smiths Medical to market its CADD®-Solis pain management system version 3.0 with Programmed Intermittent Bolus (PIB) and Patient Controlled Analgesics (PCA) delivery in the United States.
PIB medication delivery, using the CADD®-Solis v3.0, consistently administers programmed intermittent boluses (doses) that can be supplemented by the patient, improving pain relief and reducing the need for clinical interventions.
The CADD®-Solis ambulatory infusion system, designed for nurses, anesthesiologists, pharmacists and other hospital personnel, is a state-of-the-art system that meets industry recognised standards for advanced error-reduction features in PCA pumps.
Related articles
John Crane signs five-year contract to support major oil company’s Canada complex
Read our latest company news as John Crane signs a 5-year contract with a major hydrocarbon processing complex
Find out more
John Crane awarded major 5-year Dry Gas Seal repair contract from KPO
John Crane, a global leader in rotating equipment solutions and energy transition technologies and services, and a business of Smiths Group plc, has been awarded a significant contract from Karachaganak Petroleum Operating B.V. (KPO) one of the major oil and gas operators based in Kazakhstan.
Find out more
Smiths Interconnect launches new technology to reduce power loss in industrial batteries
Innovative, environmentally friendly product provides up to 90% more energy transfer than existing offering
Find out more
